Cutler Group LP Affimed N.V. Put Options Transaction History

Cutler Group LP

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2022 Oct 25, 2022	SELL	$1.96 - $3.32 $2,352 - $3,984	-1,200 Reduced 7.84%	14,100 $11,000
Q2 2022 Aug 04, 2022	BUY	$2.27 - $4.86 $34,731 - $74,358	15,300 New	15,300 $11,000
Q1 2022 Apr 14, 2022	SELL	$3.69 - $5.65 $2,214 - $3,390	-600 Closed	0 $0
Q4 2021 Jan 18, 2022	BUY	$5.37 - $7.07 $2,148 - $2,828	400 Added 200.0%	600 $1,000
Q3 2021 Oct 26, 2021	SELL	$5.54 - $7.51 $40,996 - $55,574	-7,400 Reduced 97.37%	200 $1,000
Q2 2021 Jul 19, 2021	BUY	$7.78 - $11.4 $51,348 - $75,240	6,600 Added 660.0%	7,600 $2,000
Q3 2018 Nov 07, 2018	BUY	$1.45 - $6.15 $1,450 - $6,150	1,000 New	1,000 $3,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.